Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis

Sands et al. demonstrated that 12-week treatment of tulisokibart, a monoclonal antibody targeting TL1A, significantly improved clinical remission rates compared to placebo in patients with moderate-to-severe ulcerative colitis.

The study included patients with a history of glucocorticoid dependence or prior treatment failure and assessed the efficacy and safety of intravenous tulisokibart.

Keywords: